Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 4/20 | 0.56 |
| ▸ | POLB | P06746 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.55 |
| ▸ | HPGD | P15428 | 2/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.55 |
| ▸ | MMP8 | P22894 | 1/20 | 0.52 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | NPC1 | O15118 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | RAB9A | P51151 | 1/20 | 0.51 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6387804 | 0.97 | EPHX2 (0.60) | EPHX2POLBKMT2AHPGDALDH1A1 | |
| SCHEMBL6391334 | 0.97 | EPHX2 (0.56) | EPHX2POLBKMT2AHPGDALDH1A1 | |
| SCHEMBL6391297 | 0.94 | NPC1 (0.58) | EPHX2POLBKMT2AHPGDALDH1A1 | |
| SCHEMBL6394738 | 0.93 | EPHX2 (0.61) | EPHX2POLBKMT2AHPGDALDH1A1 | |
| SCHEMBL6394268 | 0.90 | NPC1 (0.60) | EPHX2POLBKMT2AALDH1A1MMP8 | |
| SCHEMBL6390673 | 0.85 | EPHX2 (0.52) | EPHX2POLBKMT2AHPGDALDH1A1 | |
| SCHEMBL2284133 | 0.85 | L3MBTL1 (0.46) | POLBALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL6390561 | 0.84 | EPHX2 (0.51) | EPHX2POLBKMT2AHPGDALDH1A1 | |
| SCHEMBL15093363 | 0.83 | EPHX2 (0.77) | EPHX2POLBKMT2AHPGDALDH1A1 | |
| SCHEMBL6387806 | 0.83 | EPHX2 (0.56) | EPHX2POLBKMT2AHPGDALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050192347-A1 | Urea and thiourea compounds and compositions for cholesterol management and related uses | ESPERION THERAPEUTICS, INC. | 2005-09-01 | — | — | US | claimed |
| US-20050192347-A1 | Urea and thiourea compounds and compositions for cholesterol management and related uses | ESPERION THERAPEUTICS, INC. | 2005-09-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050192347-A1 | Urea and thiourea compounds and compositions for cholesterol management and related uses | PNLIP, FABP2, GPR119 | EPHX2 3605/4885POLB 2521/4885KMT2A 4598/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.